Open Access<p>Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations</p>
Author(s) -
Yimeng Geng,
Yeling Mei,
Ying Xi,
Jian Yu,
Ke Meng,
Téngfēi Zhāng,
Wei Ma
Publication year - 2020
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s266477
Subject(s) - medicine , bilirubin , lung cancer , gastroenterology , univariate analysis , epidermal growth factor receptor , oncology , adenocarcinoma , multivariate analysis , cancer
Non-small cell lung cancer (NSCLC) patients with an epidermal growth factor receptor ( EGFR ) mutation demonstrate only a median progression-free survival (PFS) of 8 to 10 months and undergo EGFR tyrosine kinase inhibitors (EGFR-TKIs) therapy. For decades, bilirubin has been reported to be associated with the onset and prognosis of lung cancer as a prooxidant. This study aimed to investigate the prediction of pretreatment circulating bilirubin for PFS in lung adenocarcinoma (LAC) patients who underwent EGFR-TKIs targeted therapy.